Pfizer And J&J Settle Remicade Antitrust Litigation
Long-Running Case Over Infliximab Biosimilars Resolved On Confidential Terms
Executive Summary
Pfizer and Johnson & Johnson have settled long-running US antitrust litigation over claims that contracts and deals for the Remicade brand were set up to dampen competition from infliximab biosimilars.
You may also be interested in...
Regeneron CEO Takes Industry Counterview On FTC Suit: ‘I’m Glad They’re Looking Into This’
Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit in response to the FTC’s effort to stop Amgen’s acquisition of Horizon.
Regeneron CEO Takes Industry Counterview On FTC News: “I’m Glad They’re Looking Into This”
Leonard Schleifer said it is time for US regulators to review whether certain rebate practices are anti-competitive, while speaking at the Financial Times US Pharma & Biotech Summit.
IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.